Biopharma companies use Contract Development and Manufacturing Organizations (CDMOs) extensively for process development, scale-up and manufacturing and have come to rely on them. It’s important to choose a CDMO that will be a good fit because getting it wrong could have disastrous consequences for progressing therapeutics to market.

We surveyed Biopharma decision makers involved in the selection of a CDMO to find out what’s important in the selection process, what challenges companies face and what working with a CDMO is like.

The report aims to help guide companies in their choice of CDMO partner which can ultimately speed the commercialization of therapeutics.